Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

- (10) ------------------------- Net loss $ 3,044 $ 2,409 Condensed Consolidated Balance Sheets (in thousands) March 31, December 31, 2010 2009 (unaudited) Assets: Cash, cash equivalents and short term investments $ 47,586 $ 64,568 Restricted cash 3,502 - Amounts receivable 2,823 3,109 Prepaid and other current assets 1,938 722 Property, equipment and other assets 589 581 ------------------------- Total assets 56,438 $ 68,980 ------------------------- ------------------------- Liabilities and stockholders' equity: Accounts payable and accrued expenses 6,824 $ 14,453 Deferred collaboration revenue 24,611 26,528 Other current liabilities 1,307 1,328 Long term liabilities 3,427 3,712 Stockholders' equity (deficiency) 20,269 22,959 ------------------------- Total liabilities and stockholders' equity (deficiency) 56,438 $ 68,980 -------------------------
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... the Company,s Investor Day in New ... syndrome (IBS) program, including its novel, oral product ... the keynote presentation, Mark Pimentel , MD, ...
(Date:9/16/2014)... Oro Valley, Arizona (PRWEB) September 16, 2014 ... company that develops safe and effective products to ... through the use of a proprietary SPACEā„¢ Technology ... Executive Officer and President will present at the ... 18, 2014 at the Hyatt Regency Phoenix. ...
(Date:9/16/2014)... , Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers ... (BMSi) test identifies patients with bone fragility fracture ... 160 million people worldwide are at risk of ... today,s standard bone strength test, the DEXA bone ... American Society for Bone and Mineral Research Annual ...
(Date:9/16/2014)... NEW ORLEANS , Sept. 16, 2014 ... Austin, Texas -based cybersecurity company focused on ... 2FA ONE, will support the ability to generate a ... As a pioneer of user-based RFID authentication, ... used for physical access, for many years. RFID authentication ...
Breaking Biology Technology:Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 32FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2
... Incorporated (Nasdaq: SPEX ), an innovator in ... and providers of technical and regulatory consulting services to ... its President, Dr. Robert Lodder, will be presenting at ... Dr. Lodder will deliver the Company,s corporate presentation ...
... IRVING, Texas, Jan. 5, 2011 Signal Genetics, the ... predictive genetic testing company focused on oncology, and Caris ... enabling precise and personalized healthcare through the highest quality ... announced a new agreement under which Caris Life Sciences ...
... Corporation (Nasdaq: VRNM ), a pioneer in ... today announced that James Levine, Executive Vice President and ... Jaffray Sixth Annual Clean Technology & Renewables Conference.  The ... on Wednesday, January 12, 2011 and will take place ...
Cached Biology Technology:Spherix to Present at Two Upcoming Prominent Finance Conferences 2Spherix to Present at Two Upcoming Prominent Finance Conferences 3Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test 2Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test 3Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 2Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference 3
(Date:9/15/2014)... both plants and animals alike. , Understanding just how ... to the design of better drugs for diabetes patients ... vegetables farmers are able to grow. Stanford University researchers ... cell by piecing together proteins slightly wider than the ... determine the size, shape and orientation of one of ...
(Date:9/15/2014)... have found "the most famous wheat gene," a reproductive ... transfer valuable genes from other plants to ... develop wheat varieties with the disease- and pest-resistance traits ... that can reduce crop losses and pesticide use while ... Modified Organisms, or GMOs., "The real exciting part of ...
(Date:9/15/2014)... WASHINGTON A new strategic vision document, released ... Research Program, describes the long-term goals, objectives, and ... scope of work over the next five years ... its initial, short-term activities, to be funded in ... and science policy fellowships. , The $500 ...
Breaking Biology News(10 mins):X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3WSU researchers find 'most famous wheat gene' 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... producing proteins that moonlight, having different roles at different ... killed. The moonlighting activity of one enzyme from the ... of broad-spectrum antibiotics, according to a paper published in ... "Glutamate racemase, or MurI, is an enzyme ...
... many recent reports documenting the therapeutic efficacy of short ... may actually be describing non-specific therapeutic effects related to ... according to a paper in the September 2008 issue ... , a peer-reviewed journal published by Mary Ann Liebert, ...
... NY, Sept. 2, 2008) People concerned about the ... families and communities will have a unique opportunity to ... about the causes, symptoms and progression of such illnesses ... learn about current and potential treatments. In an ...
Cached Biology News:Energy-saving bacteria resist antibiotics 2Previous claims of siRNA therapeutic effects called into question by report in human gene therapy 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 2Healthy Minds Across America features 48 public forums on mental health research, Sept. 14 3
Applications: Western blotting ...
...
... efficiencies and the chemistry of light production ... benefit that they require simple triggering conditions ... This benefit has been exploited to great ... compounds can also be easily modified to ...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Biology Products: